Compare Expensify Inc (EXFY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Sana Biotechnology Inc — how do they compare? Expensify Inc trades at $2.4 (market cap $208.82M), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Sana Biotechnology Inc is far larger — about 4× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Sana Biotechnology Inc for 23 Days on average.
| EXFY | SANA | |
|---|---|---|
Market Cap | $208.82M | $836.71M |
Volume | 456,102 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $2.72 | $5.92 |
52-Week Low | $0.75 | $2.68 |
Typical Hold Time | 41 Days | 23 Days |
Enterprise Value | $148.44M | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.40, up 5.73% today, showing technical bullish momentum with positive moving averages. The company reported mixed quarterly results with recent beats but maintains negative profitability metrics. Recent business developments include strategic AI integrations and European expansion of its corporate card program, signaling growth initiatives despite ongoing net losses.
The outlook remains speculative with analyst consensus pointing to significant upside potential ($13.75 target) but fundamental challenges persist including negative margins and cash flow volatility. Key risks include execution on AI transition and competitive pressure in expense management software, while institutional sentiment leans bullish with 50% buy ratings.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
